Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) was upgraded by research analysts at ValuEngine from a “strong sell” rating to a “sell” rating in a research note issued on Thursday.

Separately, Wells Fargo & Company raised shares of Infinity Pharmaceuticals from a “market perform” rating to an “outperform” rating in a research note on Thursday.

Infinity Pharmaceuticals (NASDAQ:INFI) traded up 123.35% during mid-day trading on Thursday, hitting $3.73. 61,230,511 shares of the stock traded hands. Infinity Pharmaceuticals has a 12-month low of $0.84 and a 12-month high of $3.84. The company has a 50 day moving average of $1.28 and a 200-day moving average of $1.65. The stock’s market cap is $189.07 million.

Infinity Pharmaceuticals (NASDAQ:INFI) last announced its quarterly earnings data on Thursday, August 3rd. The biotechnology company reported ($0.34) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.22) by ($0.12). During the same quarter in the prior year, the business earned $1.05 EPS. Equities research analysts forecast that Infinity Pharmaceuticals will post ($0.92) earnings per share for the current year.

TRADEMARK VIOLATION WARNING: “Infinity Pharmaceuticals, Inc. (INFI) Upgraded to Sell at ValuEngine” was first reported by American Banking News and is owned by of American Banking News. If you are viewing this report on another website, it was copied illegally and republished in violation of United States and international copyright law. The correct version of this report can be viewed at https://www.americanbankingnews.com/2017/10/12/infinity-pharmaceuticals-inc-infi-upgraded-to-sell-at-valuengine.html.

In related news, insider Value Fund L. P. Biotechnology bought 1,600,046 shares of the firm’s stock in a transaction on Wednesday, October 4th. The shares were bought at an average cost of $1.26 per share, for a total transaction of $2,016,057.96. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 6.81% of the company’s stock.

Hedge funds and other institutional investors have recently modified their holdings of the business. Zacks Investment Management purchased a new stake in shares of Infinity Pharmaceuticals during the 2nd quarter worth $101,000. Highbridge Capital Management LLC purchased a new stake in shares of Infinity Pharmaceuticals in the 1st quarter worth about $106,000. Ameriprise Financial Inc. purchased a new stake in shares of Infinity Pharmaceuticals in the 2nd quarter worth about $130,000. LMR Partners LLP purchased a new stake in shares of Infinity Pharmaceuticals in the 2nd quarter worth about $222,000. Finally, Wells Fargo & Company MN boosted its position in shares of Infinity Pharmaceuticals by 144.6% in the 1st quarter. Wells Fargo & Company MN now owns 81,493 shares of the biotechnology company’s stock worth $263,000 after buying an additional 48,177 shares in the last quarter. Institutional investors own 67.47% of the company’s stock.

Infinity Pharmaceuticals Company Profile

Infinity Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and delivery of medicines to treat diseases. The Company develops small molecule drugs that target disease pathways for potential applications in oncology. Its product candidate is duvelisib, also known as IPI-145, is an oral, dual-inhibitor of the delta and gamma isoforms of phosphoinositide-3-kinase (PI3K), for the treatment of hematologic malignancies, or blood cancers.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Infinity Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Infinity Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.